Novartis AG revised earnings guidance for the year 2024. For the year, net sales now expected to grow high single to low double-digit compared to the previous guidance of from mid-single-digit and core operating income now expected to grow low double-digit to mid-teens compared to the previous guidance of from high single-digit.